Study on Using Olaparib Alone or with Cediranib Compared to Standard Chemotherapy for Women with Certain Types of Ovarian Cancer

Program Overview

The purpose of this study is to compare the effectiveness of Olaparib, either alone or combined with Cediranib, against standard chemotherapy in treating women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and responds to platinum-based treatments. Olaparib and Cediranib may help stop cancer growth by blocking certain enzymes and blood vessels needed for tumors to grow. The study aims to find out if these drugs can work better than traditional chemotherapy drugs like carboplatin and paclitaxel.

Description

This study is divided into three treatment groups:

• Group 1: Patients receive standard chemotherapy, which may include drugs like paclitaxel, carboplatin, gemcitabine, or pegylated liposomal doxorubicin. These drugs are given through an IV and the treatment cycles repeat every 21 or 28 days, depending on the regimen, for at least four cycles.

• Group 2: Patients take Olaparib pills twice a day. Treatment cycles repeat every 28 days as long as the cancer does not progress and side effects are manageable.

• Group 3: Patients take Olaparib pills twice a day and Cediranib pills once a day. Treatment cycles repeat every 28 days as long as the cancer does not progress and side effects are manageable.

Throughout the study, patients will undergo various tests, including heart scans, CT or MRI scans, and blood tests, to monitor their health and the effectiveness of the treatment. After completing the study treatment, patients will have follow-up visits every three months for two years, then every six months for three more years.

Eligibility Criteria

Locations